[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"doc-seo-350850-105":3,"detail-sidebar-cat-0-en-105":81,"doc-detail-350850-en":130},{"code":4,"msg":5,"data":6},0,"ok",{"site_id":7,"language":8,"slug":9,"title":10,"keywords":11,"description":12,"schema_data":13,"social_meta":74,"head_meta":76,"extra_data":78,"updated_unix":80},105,"en","prior-therapy-defines-mutation-profiles-in-childhood-cancer-at-relapse-received-3-march-2025-published-online-22-july-2026","Prior therapy defines mutation profiles in childhood cancer at relapse - Received 3 March 2025 - Published online 22 July 2026","","Childhood cancer treatments can produce many short- and long-term side-effects, yet the extent of DNA damage linked to chemotherapy remains unclear. Using mutational signatures on whole-genome sequenced tumours from a multi-institutional cohort with uniformly collected therapy dose and exposure, chemotherapy and radiotherapy emerge as key exogenous mutagens in relapsed tumours. Post-therapy cancers show substantially more private signatures and somatic mutations than treatment-naive tumours. Mutagenic effects differ across chemotherapies, with platinum regimens producing the earliest detectable platinum signatures in over one-third of cases within one year, supporting therapy-driven tumour evolution, tracking resistant clones, and possible treatment de-escalation.",{"@graph":14,"@context":73},[15,34,56],{"@type":16,"itemListElement":17},"BreadcrumbList",[18,23,27,31],{"item":19,"name":20,"@type":21,"position":22},"https://docshare.wps.com","Home","ListItem",1,{"item":24,"name":25,"@type":21,"position":26},"https://docshare.wps.com/document/","Document",2,{"item":28,"name":29,"@type":21,"position":30},"https://docshare.wps.com/document/research-report/","Research & Report",3,{"item":32,"name":10,"@type":21,"position":33},"https://docshare.wps.com/document/prior-therapy-defines-mutation-profiles-in-childhood-cancer-at-relapse-received-3-march-2025-published-online-22-july-2026/350850/",4,{"url":32,"name":10,"@type":35,"image":36,"author":41,"headline":10,"publisher":44,"fileFormat":47,"inLanguage":8,"description":12,"dateModified":48,"datePublished":49,"encodingFormat":47,"isAccessibleForFree":50,"interactionStatistic":51},"DigitalDocument",{"url":37,"@type":38,"width":39,"height":40},"https://docshare.wps.com/thumbnails/prior-therapy-defines-mutation-profiles-in-childhood-cancer-at-relapse-received-3-march-2025-published-online-22-july-2026/350850.png","ImageObject",300,407,{"name":42,"@type":43},"moss~","Person",{"url":19,"name":45,"@type":46},"DocShare","Organization","application/pdf","2026-10-23","2026-09-22",true,{"@type":52,"interactionType":53,"userInteractionCount":55},"InteractionCounter",{"@type":54},"ViewAction",8,{"@type":57,"mainEntity":58},"FAQPage",[59,65,69],{"name":60,"@type":61,"acceptedAnswer":62},"Why did the study use mutational signatures in relapsed childhood cancer?","Question",{"text":63,"@type":64},"To quantify chemotherapy- and radiotherapy-associated DNA damage by measuring mutational signatures in whole-genome sequenced tumours.","Answer",{"name":66,"@type":61,"acceptedAnswer":67},"How do post-therapy tumours compare with treatment-naive tumours in mutation patterns?",{"text":68,"@type":64},"Post-therapy cancers carried nearly three times the number of private signatures and about twice the total burden of somatic mutations.",{"name":70,"@type":61,"acceptedAnswer":71},"What did the study find about platinum-based chemotherapy and the timing of detectable mutations?",{"text":72,"@type":64},"More than one-third of tumours treated with platinum drugs displayed detectable platinum signatures within one year, enabling a minimum threshold for signature emergence based on therapy exposure dates.","https://schema.org",{"og:url":32,"og:type":75,"og:title":10,"og:site_name":45,"og:description":12},"article",{"robots":77,"canonical":32},"index,follow",{"doc_id":79,"site_id":7},350850,1790468230,{"code":4,"msg":82,"data":83},"success",[84,88,92,96,101,106,111,114,119,122,126],{"id":22,"doc_module":4,"doc_module_name":25,"category_name":85,"show_sort_weight":86,"slug":87},"Story & Novel",90,"story-novel",{"id":26,"doc_module":4,"doc_module_name":25,"category_name":89,"show_sort_weight":90,"slug":91},"Literature",80,"literature",{"id":33,"doc_module":4,"doc_module_name":25,"category_name":93,"show_sort_weight":94,"slug":95},"Exam",70,"exam",{"id":97,"doc_module":4,"doc_module_name":25,"category_name":98,"show_sort_weight":99,"slug":100},5,"Comic",60,"comic",{"id":102,"doc_module":4,"doc_module_name":25,"category_name":103,"show_sort_weight":104,"slug":105},6,"Technology",50,"technology",{"id":107,"doc_module":4,"doc_module_name":25,"category_name":108,"show_sort_weight":109,"slug":110},7,"Healthcare",40,"healthcare",{"id":55,"doc_module":4,"doc_module_name":25,"category_name":29,"show_sort_weight":112,"slug":113},30,"research-report",{"id":115,"doc_module":4,"doc_module_name":25,"category_name":116,"show_sort_weight":117,"slug":118},9,"Religion & Spirituality",20,"religion-spirituality",{"id":117,"doc_module":4,"doc_module_name":25,"category_name":120,"show_sort_weight":117,"slug":121},"World Cup","world-cup",{"id":123,"doc_module":4,"doc_module_name":25,"category_name":124,"show_sort_weight":123,"slug":125},10,"Lifestyle","lifestyle",{"id":127,"doc_module":4,"doc_module_name":25,"category_name":128,"show_sort_weight":97,"slug":129},19,"General","general",{"code":4,"msg":82,"data":131},{"doc_id":79,"user_id":132,"nickname":42,"user_avatar":133,"doc_module":4,"category_id":55,"category_name":29,"doc_title":10,"doc_description":12,"doc_content":134,"file_id":135,"file_url":136,"file_type":137,"file_size":138,"view_count":55,"is_deleted":4,"is_public":22,"is_downloadable":22,"audit_status":22,"page_count":139,"language":140,"language_code":8,"site_id":7,"html_lang":8,"table_of_contents":141,"faqs":142,"seo_title":143,"seo_description":12,"update_tm":144,"read_time":145,"preview_page_count":33,"preview_urls":146},962090895452,"https://ap-avatar.wpscdn.com/davatar_a8503ba1806abce46bf441b54a3ca4cd","Article  \n\n| Prior therapy defines mutation profilesin childhood cancer at relapse |  |  |\n| --- | --- | --- |\n| [https://doi.org/10.1038/s41586-026-10803-1](https://doi.org/10.1038/s41586-026-10803-1)\u003Cbr>Received: 3 March 2025 Accepted: 12 June 2026 Published online: 22 July 2026 Open access\u003Cbr> Check for updates | Mehdi Layeghifard1, Marcos Díaz-Gay2, Erik N. Bergstrom3,4,5, Mathepan J. Mahendralingam1,6, Nicholas Light1, Sasha Blay1,6, Joshua O. Nash1,6, Nathaniel D. Anderson1, Jessica N. Au3,4,5,7, Scott Davidson1, Pedro L. Ballester1, Timmy Wen1, Syed Kashif Daud1, Lisa-Monique Edward1, S. M. Ashiqul Islam8, Azhar Khandekar3,4,5, Burçak Otlu9, Ledia Brunga1, Rawan Hammad10,11, Shimaa Nassif12, Nirav H. Thacker12, Tara Feltham13, Noemi A. Fuentes-Bolanos14,15,\u003Cbr>Marie Wong-Erasmus14,15, Max F. Levine16, Katherine E. Miller17,18, Neerav N. Shukla16, Michael D. Kinnaman16, Dominik Glodzik19, Carol Portwine20, Sabrina Millson20,\u003Cbr>Alexandra P. Zorzi21, Mariam Mikhail21, Conrad V. Fernandez22, Laura Wheaton23,\u003Cbr>Gunes Gundem16, Andrew L. Kung16, Uri Tabori24, Chelsea Mayoh14,15, Elli Papaemmanuil16, Mark J. Cowley14,15, David Malkin1,12,25, Anita Villani12,25, Ludmil B. Alexandrov3,4,5 &\u003Cbr>Adam Shlien1,6,13 ✉\u003Cbr>Children with cancer develop many short-and long-term side-effects of treatment1, but the amount of DNA damage associated with chemotherapy exposure is unclear2. Here we used mutational signatures to measure this damage using whole-genomesequenced tumours from a multi-institutional cohort for which therapy dose and total exposure were uniformly collected3–5. Chemotherapy and radiotherapy were the only exogenous mutagens in relapsed childhood tumoursand were often the dominant source of DNA alteration. Compared with treatment-naive tumours, post-therapy cancers carried nearly three times the number of private signatures, and two times the total burden of somatic mutations. Further, the mutagenic effects of different chemotherapies varied. Platinum-based therapies, for which we more than doubled the number of associated signatures, led to the highest number of variants inmost patients. Using therapy exposure dates to track when therapy-associated mutations become detectable, we defined a minimum threshold for platinumassociated mutations toemerge. Remarkably, more than one-third of tumours treated with platinum drugs displayed detectable platinum signatures within one year. This work provides genomic evidence for the critical mutagenic effects of chemotherapy in childhood cancer, asa specific driver of tumour evolution. These data highlight opportunities for treatment de-escalation and the future possibility of tracking resistant clones before expansion. |  |\n| The substantial improvement in childhood cancer survival rates has |  | Chemotherapies can be associated with characteristic patterns of |\n| been achieved in part through therapy intensification, often atthe |  | mutations found in the tumour genome, known as mutational signa- |\n| cost of lifelong secondary effects6–11. Exposure to genotoxic radiation |  | tures2. These signatures are potentially associated with the response of |\n| therapy and chemotherapy leads to chronic long-term physical and |  | the patient to therapy, since to display them cancer cells must survive |\n| psychological complications, including growth hormone deficiency, |  | the therapy to which they were exposed19–22. A comprehensive iden- |\n| hearing loss, obesity, cardiotoxicity, reproductive failure, endocrine |  | tification of these signatures in childhood cancers could, therefore, |\n| system disruption, pulmonary dysfunction anda profound reduction |  | guide treatment decisions, including therapy de-escalation. However, |\n| in cognitive capacity12,13. In general, survivors of childhood cancer are |  | past studies have been hampered by the inclusion of small numbers |\n| 1.5–8 times more likely to develop a severe or life-threatening condi- |  | of post-therapy tumours23,24, the use ","cbCaiqeIDGFwLRQj","https://ap.wps.com/l/cbCaiqeIDGFwLRQj","pdf",35187717,31,"English","# Background\n## Clinical need and limitations of prior studies\n# Methods\n## Mutational signature analysis in whole-genome sequenced cohorts\n# Results\n## Chemotherapy and radiotherapy as dominant exogenous mutagens\n## Increased private signatures and somatic mutation burden after therapy\n## Chemotherapy-specific mutagenic patterns, especially platinum\n# Implications\n## Timing of mutation detectability, resistant clone tracking, and de-escalation opportunities","[{\"question\":\"Why did the study use mutational signatures in relapsed childhood cancer?\",\"answer\":\"To quantify chemotherapy- and radiotherapy-associated DNA damage by measuring mutational signatures in whole-genome sequenced tumours.\"},{\"question\":\"How do post-therapy tumours compare with treatment-naive tumours in mutation patterns?\",\"answer\":\"Post-therapy cancers carried nearly three times the number of private signatures and about twice the total burden of somatic mutations.\"},{\"question\":\"What did the study find about platinum-based chemotherapy and the timing of detectable mutations?\",\"answer\":\"More than one-third of tumours treated with platinum drugs displayed detectable platinum signatures within one year, enabling a minimum threshold for signature emergence based on therapy exposure dates.\"}]","Prior therapy defines mutation profiles in childhood cancer at relapse - Received 3 March 2025 - Published online 22 July 2026 | PDF",1790091495,78,[147,151,155,159],{"page_no":22,"url":148,"width":149,"height":150},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/b65513126dbc9568a3a1625b5301216c.webp",983,1305,{"page_no":26,"url":152,"width":153,"height":154},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/65641d21cae294dd30f36ddd905f1029.webp",982,1304,{"page_no":30,"url":156,"width":157,"height":158},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/17c547d3aa1ea7d4fb422ed641f26d68.webp",981,1303,{"page_no":33,"url":160,"width":161,"height":162},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/26b1bdbeb2dc30b8812cd82f22ec80cb.webp",980,1301]